Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

  • End date
    Feb 2, 2024
  • participants needed
  • sponsor
    Centre Hospitalier Universitaire de Besancon
Updated on 2 April 2021
karnofsky performance status
treatment regimen
liver metastasis
serum calcium
kidney cancer


Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the consultation as part of their usual care. The patients will be included before Sunitinib treatment is started. Thereafter, sunitinib is initiated 50 mg/day; regimen 4/6 (Marketing Authorisation Indication), 4 weeks "on " alternating with 2 weeks "off "

As soon as a dose or schedule adjustment is required, regardless of cause, the patient will be randomised 1/1:

  • Either into arm A and will receive 37.5mg of Sunitinib per day by the 4/6 regimen (in accordance with the Marketing Authorisation); 4 weeks "on " alternating with 2 weeks "off "
  • Or into arm B and will receive 50mg of Sunitinib per day by the 2/3 regimen (investigational arm); 2 weeks "on " alternating with 1 week "off "

Condition urinary tract neoplasm, Malignant neoplasm of kidney, Nephropathy, Kidney Disease (Pediatric), Metastatic Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Metastatic Kidney Cancer, Kidney Cancer, Kidney Disease, Renal Cancer, Urologic Cancer, kidney tumor, renal tumors, neoplasia renal, renal neoplasm, renal tumor, kidney tumours, kidney tumors
Treatment Sunitinib
Clinical Study IdentifierNCT02689167
SponsorCentre Hospitalier Universitaire de Besancon
Last Modified on2 April 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Kidney Cancer or Malignant neoplasm of kidney or Kidney Disease or Metastatic Renal Cell Cancer or urinary tract neoplasm or Renal Cancer or Urologic ...?
Do you have any of these conditions: Renal Cancer or Kidney Disease or renal tumors or Kidney Disease (Pediatric) or Malignant neoplasm of kidney or Metastatic Kidney Cancer or Metastatic...?
Do you have any of these conditions: renal tumor or Metastatic Renal Cell Cancer or Kidney Disease (Pediatric) or kidney tumor or neoplasia renal or renal tumors or Metastatic Renal Cell ...?
Do you have any of these conditions: neoplasia renal or kidney tumors or Metastatic Renal Cell Carcinoma or Malignant neoplasm of kidney or Metastatic Kidney Cancer or Kidney Disease or N...?
Men or women over 18 years old
Patients with local, advanced or inoperable or metastatic (MRCC) renal cell carcinoma who are starting first line treatment with Sunitinib 50mg (4/6 regimen) according to the Marketing Authorisation Indication
Patients with histologically or cytologically confirmed renal cancer, clear cell variant or with a clear cell component
Karnofsky performance status 70%
Adequate organ function
Absolute neutrophil (N) count 1 500 / L
Platelets 100 000 / L
Haemoglobin 10 g/dL
Adjusted serum calcium 2.6 mmol/L
Creatinine clearance 30 mL/min (by the MDRD formula)
Total bilirubin 1.5 x ULN (upper limit of the normal range)
AST 2.5 x ULN and ALT 2.5 x ULN OR AST and ALT 5 x ULN if liver abnormalities due to liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase

Exclusion Criteria

Renal carcinoma with no clear cell component
Previous systemic treatment for the RCC regardless of type (including targeted therapy, immunotherapy, chemotherapy, hormone or experimental therapy). Previous or concomitant treatment with a bisphosphonate or denosumab is allowed
Patients whose clinical state and comorbidities are not consistent with administration of Sunitinib at the initial dose of 50mg/day 4 weeks out of 6
Grade 3 haemorrhage within 4 weeks before starting treatment with Sunitinib (according to the NCI-CTCAE toxicity score version 3.0)
The presence of a past history of cancer in the 3 years before inclusion into the study
Major surgery within 4 weeks before sunitinib initiation
Past history of symptomatic cerebral metastases, spinal cord compression or meningeal carcinomatosis. Patients with cerebral metastases discovered incidentally on imaging and who are asymptomatic are not excluded if these metastases have been treated (radiotherapy and/or surgery) with a period of at least 4 weeks between the end of treatment and inclusion into the study and no clinical or radiological signs of relapse, and corticosteroid dose is not exceeding 10mg/day of prednisone or equivalent. Subjects will be excluded if subjects have signs of grade 2 treatment-related complications
Any of the following features within 6 months of the administration of Sunitinib: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack
Pulmonary embolism or deep vein thrombosis within 3 months of inclusion (unless it's stable, asymptomatic and treated with a low molecular weight heparin for at least 6 weeks before inclusion)
Any known acute or chronic disorder (such as severe chronic obstructive pulmonary disease) which in the opinion of the investigator could impact on the patient's capacity to receive the study treatment or make interpretation of toxicity or adverse events difficult
Known HIV infection
History of chronic active hepatitis including subjects who are carriers of the hepatitis B (HBV) or hepatitis C (HCV) virus
Existence of uncontrolled infection
Uncontrolled hypertension defined as a blood pressure of > 150 mmHg systolic or > 100 mmHg diastolic despite optimal anti-hypertensive therapy (blood pressure must be controlled at inclusion)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note